Abstract

In this paper a review of the researches on the role of Escherichia coli strain Nissle 1917 (EcN) in gastrointestinal diseases was presented. EcN is a non-pathogenic strain of the Enterobacteriaceae family, which has probiotic properties. In a number of studies conducted among humans and experimental animals the application of EcN in treatment of gastrointestinal diseases was observed. Most studies about EcN has been devoted to this organism efficacy in ulcerative colitis treatment. Comparable results were obtained, by citied authors, in the treatment (sustaining remission) of EcN and mesalazine in ulcerative colitis. Moreover, this probiotic therapy, compared to placebo, contributes to obtaining a faster remission and improvement of intestinal histopathology. The use of EcN in Crohn’s disease has not been the subject of as many studies as in the case of ulcerative colitis. Assessing the importance of EcN in treatment of other gastrointestinal disorders, authors of the studies observed, that in patients with irritable bowel syndrome, who receiving this probiotic there was a pain, nausea and bloating reduction. In studies conducted among children a positive impact of EcN in prevention and treatment of diarrhea was demonstrated. Similar results were obtained in studies conducted in experimental animals. Based on the presented review it can be concluded that the strain of Escherichia coli Nissle 1917 is useful in treatment of gastrointestinal diseases, especially in treatment of ulcerative colitis. This probiotic may constitute a part of treatment of irritable bowel syndrome and diarrhea. The effectiveness of this strain in treatment of Crohn’s disease is not clearly established and further research are require.

References

• 1. Altenhoefer A., Oswald S., Sonnenborn U., Enders C., Schulze J.,Hacker J., Oelschlaeger T.A.: The probotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cellsby different enteroinvasive bacterial pathogens. FEMS Immunol.Med. Microbiol., 2004; 40: 223-229
  Google Scholar
• 2. Banasiewicz T., Borycka-Kiciak K., Dobrowolska-Zachwieja A.,Friediger J., Kiciak A., Krokowicz P., Małecka-Panas E., Pietrzak P.,Rydzewska G., Tarnowski W., Zabielski R.: Kliniczne aspekty zastosowaniakwasu masłowego w postępowaniu dietetycznym w chorobachjelit. Przegl. Gastroenterol., 2010; 5: 329-334
  Google Scholar
• 3. Bartnik W.: Wytyczne postępowania w nieswoistych chorobachzapalnych jelit. Przegl. Gastroenterol., 2007; 2: 215-229
  Google Scholar
• 4. Boudeau J., Glasser A.L., Julien S., Colombel J.F., Darfeuille-MichaudA.: Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasiveE. coli strains isolated from patients with Crohn’sdisease. Aliment. Pharmacol. Ther., 2003; 18: 45-56
  Google Scholar
• 5. Cukrowska B., Lodinová-Zádniková R., Enders C., SonnenborgU., Schulze J., Tlaskalová-Hogenová H.: Specific proliferative andantibody responses of premature infants to intestinal colonizationwith nonpathogenic probiotic E. coli strain Nissle 1917. Scand. J. Immunol.,2002; 55: 204-209
  Google Scholar
• 6. Duncker S.C., Lorentz A., Schroeder B., Breves G., Bischoff S.C.:Effect of orally administered probiotic E. coli strain Nissle 1917 onintestinal mucosal immune cells of healthy young pigs. Vet. Immunol.Immunopathol., 2006; 111: 239-250
  Google Scholar
• 7. Eder P., Łodyga M., Łykowska-Szuber L., Bartnik W., Durlik M.,Gonciarz M., Kłopocka M., Linke K., Małecka-Panas E., Radwan P.,Rydzewska G.: Wytyczne Grupy Roboczej Konsultanta Krajowegow dziedzinie Gastroenterologii i Polskiego Towarzystwa Gastroenterologiidotyczące postępowania z pacjentem z wrzodziejącym zapaleniemjelita grubego. Przegl. Gastroenterol., 2013; 8: 1-20
  Google Scholar
• 8. Henker J., Laass M., Blokhin B.M., Bolbot Y.K., Maydannik V.G.,Elze M., Wolff C., Schulze J.: The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur. J. Pediatr.,2007; 166: 311-318
  Google Scholar
• 9. Hernando-Harder A.C., von Bünau R., Nadarajah M., Singer M.V.,Harder H.: Influence of E. coli strain Nissle 1917 (EcN) on intestinalgas dynamics and abdominal sensation. Dig. Dis. Sci., 2008; 53:443-450
  Google Scholar
• 10. Kamada N., Inoue N., Hisamatsu T., Okamoto S., Matsuoka K.,Sato T., Chinen H., Hong K.S., Yamada T., Suzuki Y., Suzuki T., WatanabeN., Tsuchimoto K., Hibi T.: Nonpathogenic Escherichia coli strainNissle 1917 prevents murine acute and chronic colitis. Inflamm.Bowel Dis., 2005; 11: 455-463
  Google Scholar
• 11. Kamada N., Maeda K., Inoue N., Hisamatsu T., Okamoto S., HongK.S., Yamada T., Watanabe N., Tsuchimoto K., Ogata H., Hibi T.: NonpathogenicEscherichia coli strain Nissle 1917 inhibits signal transductionin intestinal epithelial cells. Infect. Immun., 2008; 76: 214-220
  Google Scholar
• 12. Kotunia A., Pietrzak P., Guilloteau P., Zabielski R.: Kwas masłowyw przewodzie pokarmowym. Przegl. Gastroenterol., 2010; 5: 117-122
  Google Scholar
• 13. Kruis W., Chrubasik S., Boehm S., Stange C., Schulze J.: A doubleblindplacebo-controlled trial to study therapeutic effects of probioticEscherichia coli Nissle 1917 in subgroups of patients with irritablebowel syndrome. Int. J. Colorectal Dis., 2012; 27: 467-474
  Google Scholar
• 14. Kruis W., Fric P., Pokrotnieks J., Lukás M., Fixa B., Kascák M.,Kamm M.A., Weismueller J., Beglinger C., Stolte M., Wolff C., SchulzeJ.: Maintaining remission of ulcerative colitis with the probiotic Escherichiacoli Nissle 1917 is as effective as with standard mesalazine.Gut, 2004; 53: 1617-1623
  Google Scholar
• 15. Kruis W., Schütz E., Fric P., Fixa B., Judmaier G., Stolte M.: Doubleblindcomparison of an oral Escherichia coli preparation and mesalazinein maintaining remission of ulcerative colitis. Aliment. Pharmacol.Ther., 1997; 11: 853-858
  Google Scholar
• 16. Łodyga M., Eder P., Bartnik W., Gonciarz M., Kłopocka M., LinkeK., Małecka-Panas E., Radwan P., Reguła J., Rydzewska G.: WytyczneGrupy Roboczej Konsultanta Krajowego w dziedzinie Gastroenterologiii Polskiego Towarzystwa Gastroenterologii dotyczące postępowaniaz pacjentem z chorobą Leśniowskiego-Crohna. Przegl.Gastroenterol., 2012; 7: 317-338
  Google Scholar
• 17. Malchow H.A.: Crohn’s disease and Escherichia coli. A new approachin therapy to maintain remission of colonic Crohn’s disease?J. Clin. Gastroenterol., 1997; 25: 653-658
  Google Scholar
• 18. Matthes H., Krummenerl T., Giensch M., Wolff C., Schulze J.:Clinical trial: probiotic treatment of acute distal ulcerative colitiswith rectally administered Escherichia coli Nissle 1917 (EcN). BMCComplement. Altern. Med., 2010; 10: 13 doi:10.1186/1472-6882-10-13
  Google Scholar
• 19. Rembacken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M.,Axon A.T.: Non-pathogenic Escherichia coli versus mesalazine forthe treatment of ulcerative colitis: a randomised trial. Lancet, 1999;354: 635-639
  Google Scholar
• 20. Schroeder B., Duncker S., Barth S., Bauerfeind R., Gruber A.D.,Deppenmeier S., Breves G.: Preventive effects of the probiotic Escherichiacoli strain Nissle 1917 on acute secretory diarrhea in a pigmodel of intestinal infection. Dig. Dis. Sci., 2006; 51: 724-731
  Google Scholar
• 21. Schultz M., Butt G.: E. coli Nissle 1917 in the treatment of inflammatorybowel disease. Pract. Gastroenterol., 2010; 34: 11-19
  Google Scholar
• 22. Schultz M., Strauch U.G., Linde H.J., Watzl S., Obermeier F., GöttlC., Dunger N., Grunwald N., Schölmerich J., Rath H.C.: Preventive effectsof Escherichia coli strain Nissle 1917 on acute and chronic intestinalinflammation in two different murine models of colitis. Clin.Diagn. Lab. Immun., 2004; 11: 372-378
  Google Scholar
• 23. Storm D.W., Koff S.A., Horvath D.J.Jr., Li B., Justice S.S.: In vitroanalysis of the bactericidal activity of Escherichia coli Nissle 1917against pediatric uropathogens. J. Urol., 2011; 186 (Suppl. 4): 1678-1683
  Google Scholar
• 24. Szajewska H.: Probiotyki w Polsce – kiedy, jakie i dlaczego? Gastroenterol.Klin., 2010; 2: 1-9
  Google Scholar
• 25. Szajewska H., Horvath A., Dziechciarz P.: Probiotyki, prebiotykii synbiotyki w leczeniu nieswoistych zapaleń jelit – przeglądsystematyczny. Pediatr. Współcz. Gastroenterol. Hepatol. ŻywienieDziecka, 2007; 9: 266-275
  Google Scholar
• 26. von Buenau R., Jaekel L., Schubotz E., Schwarz S., Stroff T., KruegerM.: Escherichia coli strain Nissle 1917: significant reduction ofneonatal calf diarrhea. J. Dairy Sci., 2005; 88: 317-323
  Google Scholar

Full text